SYGGF.US Synairgen plc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 18, 2026
Market cap
USD 110K
P/E
-
P/B
0.01x
ROE
-100.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is SYGGF.US undervalued?

Graham number

The Graham number of Synairgen plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Synairgen plc fundamental analysis

No fundamental analysis for Synairgen plc yet.

Synairgen plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Synairgen plc

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an investigative formulation of inhaled interferon beta (IFN-ß') for the treatment and prevention of severe viral lung infections in high-risk patient groups. The company was incorporated in 2003 and is headquartered in Southampton, the United Kingdom.

Full company profile